ActivePure® Technologies partners with world famous Cleveland Clinic - double blind two year clinical study focused on reducing healthcare associated infections

Clinical Trial to Study Impact of ActivePure Technology on Surgical Site Infections DALLAS (Dec. 16, 2020)

Aerus Global formally announced the start of a double-blind two-year clinical study to evaluate the impact that ActivePure Technology can have on reducing nosocomial infections, or healthcare-associated infections, also known as HAIs, from surgical operating room procedures.

Aerus Medical Guardian with ActivePure Technology, a U.S. FDA Class II Medical Device, reduces bacteria and viruses in the air by 99.99% within 30 minutes and surface contamination by more than 99% after several hours.

The primary goal of the randomized trial will be to determine whether filtering and sterilizing operating room air with the Aerus Medical Guardian with ActivePure Technology air purifier reduces a composite of serious surgical site infections, infection-related complications, and death within 30 days after surgery.

Secondarily, the trial will determine the effect of air filtration and sterilization on serious surgical site infections and on the cost of care. HAIs are a significant concern that can have serious medical, emotional, and financial consequences.

These types of infections cost the U.S. healthcare system billions of dollars each year.

According to the Centers for Disease Control and Prevention, on any given day, about one in 31 hospital patients has at least one HAI. The Aerus Medical Study will use 50 noncardiac, adult operating rooms at Cleveland Clinic. The trial will be restricted to adults aged 18 years or older, having surgery lasting at least one hour. Patients with present-on-admission infections will be excluded from the study. Operating rooms will be randomized in onemonth blocks to Aerus air sterilization or conventional air handling. A minimum of 67,653 patients with a maximum of 86,639 patients will be needed for this study.

The trial is expected to begin this year and last approximately 2 years.

Previous
Previous

ActivePure Technologies appoints Deborah Birx M.D. key member of the USA COVID-19 Response as Chief Medical and Scientific Advisor

Next
Next

NASA-Based ActivePure® Technology Rapidly Eliminates 99.9% of Airborne SARS-CoV-2 Virus in FDA-Compliant Military Lab Tests